Remember The Basics: Dosing, Placebo Issues Recur In FDA Reviews
This article was originally published in Pharmaceutical Approvals Monthly
Fundamental trial design issues, from the selection of doses to the use of placebo controls, recur as problems in FDA reviews of new drugs. Post-market studies can remedy missing data, but at a cost.
You may also be interested in...
Regulatory flexibility is the backbone of FDA’s success in efficiently reviewing new drugs and biologics, especially on the frontiers of unmet medical needs, Pharmaceutical Approvals Monthly’s 2011 series of drug review profiles shows.
Pipeline is concentrated around Phase II, but sponsors have a few chances to see how FDA handles its ‘foundational constructs’ for psychedelic drugs, led by Lykos’ pending NDA for PTSD and Compass Pathways’ Phase III synthetic psilocybin COMP360 for treatment-resistant depression.
Flexible thinking and rigorous standards will both be needed to develop psychedelics as drug therapies in order to surmount the many complicating factors, from unique ‘set and setting’ aspects to functional unblinding, speakers at Reagan-Udall Foundation meeting agree.